Throughout my professional life, I have been extremely fortunate. Having lectured in many parts of the
country and abroad, I have listened to many people comment on the long turn-around time of journals such as the Journal of the American Academy of Dermatology and Archives of
Dermatology, with some taking as long as one year for publication of submitted materials that are novel to the field of dermatology. Taking into account this pressing need to
bring relevant dermatologic knowledge to the community faster, we launched the first issue of the Journal of Drugs in Dermatology in July 2002 with the generous support of the
pharmaceutical industry and many colleagues in the U.S. and abroad.
The first year, which comprised six issues, was remarkably successful. In 2006, we converted from six to 10
issues per year, and, in 2007, to 12 issues. Each year, the number of submitted manuscripts of outstanding quality increased substantially, allowing us to also increase the
number of manuscripts printed in each issue. With new features such as Resident Rounds, Clinical Trial Review, News Views & Reviews, Pipeline Previews, and now, Surgical
Corner, we've expanded JDD's reach to dermatology residency programs in the country, as well as monthly providing dermatologists with valuable information on current clinical
trials and focused updates on the latest developments in dermatologic therapy and techniques. Additionally, we also began releasing several supplements to the Journal per
year, bringing valuable and timely information to the dermatological community.
We are proud to have been indexed in MEDLINE®/PubMed® from Volume 1, Issue 1, and our newly received impact
factor, 1.954, is most respectable for a journal that is only now approaching its 10th year. Each year, not only do we continue to attract outstanding manuscripts from
dermatologists from this country, but we see an increase in the number of manuscripts submitted by international authors as well. Via JDDonline.com, the Journal of Drugs in
Dermatology has proudly provided worldwide access to its content to readers abroad, as well as establishing partnerships with 21 international societies. The distribution of
eJDD to 50,000 dermatologists across the globe was a groundbreaking achievement. The Journal aims to double this number within the next six months, which will no doubt give it
the largest distribution of any journal being published in the field today.
As Editor-in-Chief of JDD, I have no doubt that the numbers above will only improve in the coming years, as
the Journal has already firmly established itself as an indispensable publication in the field. This is the first of a series of editorials chronicling JDD's remarkable
achievements since its inception in 2002, and I hope you will join us in celebrating as my colleagues share their own experiences with JDD in each upcoming issue of 2012.
Perry Robins MD